Table of Contents
International Scholarly Research Notices
Volume 2014, Article ID 697617, 9 pages
http://dx.doi.org/10.1155/2014/697617
Clinical Study

A Possible Role for Pioglitazone in the Management of Depressive Symptoms in Metabolic Syndrome Patients (EPICAMP Study): A Double Blind, Randomized Clinical Trial

1Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, P.O. Box 81465-1148, Iran
2Isfahan Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, P.O. Box 81465-1148, Iran

Received 13 April 2014; Accepted 16 June 2014; Published 25 August 2014

Academic Editor: Anderson O. Wong

Copyright © 2014 Hamidreza Roohafza et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. M. Grundy, “Metabolic syndrome: a multiplex cardiovascular risk factor,” The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 2, pp. 399–404, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. M. R. Skilton, P. Moulin, J. Terra, and F. Bonnet, “Associations between anxiety, depression, and the metabolic syndrome,” Biological Psychiatry, vol. 62, no. 11, pp. 1251–1257, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Borch-Johnsen, “The metabolic syndrome in a global perspective. The public health impact—secondary publication,” Danish Medical Bulletin, vol. 54, no. 2, pp. 157–159, 2007. View at Google Scholar · View at Scopus
  4. T. Chandola, E. Brunner, and M. Marmot, “Chronic stress at work and the metabolic syndrome: prospective study,” British Medical Journal, vol. 332, no. 7540, pp. 521–524, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Carroll, A. C. Phillips, G. N. Thomas, C. R. Gale, I. Deary, and G. D. Batty, “Generalized anxiety disorder is associated with metabolic syndrome in the vietnam experience study,” Biological Psychiatry, vol. 66, no. 1, pp. 91–93, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Räikkönen, K. A. Matthews, and L. H. Kuller, “The relationship between psychological risk attributes and the metabolic syndrome in healthy women: antecedent or consequence?” Metabolism: Clinical and Experimental, vol. 51, no. 12, pp. 1573–1577, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Herva, P. Räsänen, J. Miettunen et al., “Co-occurrence of metabolic syndrome with depression and anxiety in young adults: the Northern Finland 1966 Birth Cohort Study,” Psychosomatic Medicine, vol. 68, no. 2, pp. 213–216, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. O. G. Cameron, “Anxious-depressive comorbidity: effects on HPA axis and CNS noradrenergic functions,” Essential Psychopharmacology, vol. 7, no. 1, pp. 24–34, 2006. View at Google Scholar · View at Scopus
  9. D. L. Foley, K. I. Morley, P. A. F. Madden, A. C. Heath, J. B. Whitfield, and N. G. Martin, “Major depression and the metabolic syndrome,” Twin Research and Human Genetics, vol. 13, no. 4, pp. 347–358, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Roohafza, M. Sadeghi, M. Talaei, Z. Pourmoghaddas, and N. Sarrafzadegan, “Psychological status and quality of life in relation to the metabolic syndrome: isfahan cohort study,” International Journal of Endocrinology, vol. 2012, Article ID 380902, 5 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Vogelzangs, A. T. Beekman, S. B. Kritchevsky et al., “Psychosocial risk factors and the metabolic syndrome in elderly persons: findings from the Health, Aging and Body Composition study,” Journals of Gerontology A: Biological Sciences and Medical Sciences, vol. 62, no. 5, pp. 563–569, 2007. View at Google Scholar
  12. H. Koponen, J. Jokelainen, S. Keinanen-Kiukaanniemi, E. Kumpusalo, and M. Vanhala, “Metabolic syndrome predisposes to depressive symptoms: a population-based 7-year follow-up study,” Journal of Clinical Psychiatry, vol. 69, no. 2, pp. 178–182, 2008. View at Google Scholar
  13. I. Hindmarch, “Expanding the horizons of depression: beyond the monoamine hypothesis,” Human Psychopharmacology, vol. 16, no. 3, pp. 203–218, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Capuron, S. Su, A. H. Miller et al., “Depressive symptoms and metabolic syndrome: is inflammation the underlying link?” Biological Psychiatry, vol. 64, no. 10, pp. 896–900, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. R. S. McIntyre, J. K. Soczynska, G. F. Lewis, G. M. MacQueen, J. Z. Konarski, and S. H. Kennedy, “Managing psychiatric disorders with antidiabetic agents: translational research and treatment opportunities,” Expert Opinion on Pharmacotherapy, vol. 7, no. 10, pp. 1305–1321, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. S. D. Clarke, P. Thuillier, R. A. Baillie, and X. Sha, “Peroxisome proliferator-activated receptors: a family of lipid-activated transcription factors,” The American Journal of Clinical Nutrition, vol. 70, no. 4, pp. 566–571, 1999. View at Google Scholar · View at Scopus
  17. P. O. Szapary, L. T. Bloedon, F. F. Samaha et al., “Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 1, pp. 182–188, 2006. View at Google Scholar
  18. B. García-Bueno, B. G. Pérez-Nievas, and J. C. Leza, “Is there a role for the nuclear receptor PPARγ in neuropsychiatric diseases?” International Journal of Neuropsychopharmacology, vol. 13, no. 10, pp. 1411–1429, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Shokouh, A. Joharimoghadam, H. Roohafza et al., “Effects of pioglitazone on asymmetric dimethylarginine and components of the metabolic syndrome in nondiabetic patients (EPICAMP Study): a double-blind, randomized clinical trial,” PPAR Research, vol. 2013, Article ID 358074, 9 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Sarraf-Zadegan, G. Sadri, and A. H. Malek, “Isfahan Healthy Heart Programme: a comprehensive integrated community-based programme for cardiovascular disease prevention and control. Design, methods and initial experience,” Acta Cardiologica, vol. 58, no. 4, pp. 309–320, 2003. View at Publisher · View at Google Scholar
  21. K. G. Alberti, R. H. Eckel, S. M. Grundy et al., “Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity,” Circulation, vol. 120, no. 16, pp. 1640–1645, 2009. View at Publisher · View at Google Scholar
  22. American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 43, supplement 1, pp. S62–S69, 2011. View at Google Scholar
  23. A. Montazeri, M. Vahdaninia, M. Ebrahimi, and S. Jarvandi, “The Hospital Anxiety and Depression Scale (HADS): translation and validation study of the Iranian version,” Health and Quality of Life Outcomes, vol. 1, p. 14, 2003. View at Google Scholar
  24. A. S. Zigmond and R. P. Snaith, “The hospital anxiety and depression scale,” Acta Psychiatrica Scandinavica, vol. 67, no. 6, pp. 361–370, 1983. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Montazeri, A. M. Harirchi, M. Shariati, G. Garmaroudi, M. Ebadi, and A. Fateh, “The 12-item General Health Questionnaire (GHQ-12): translation and validation study of the Iranian version,” Health and Quality of Life Outcomes, vol. 1, article 66, 2003. View at Google Scholar
  26. D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner, “Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man,” Diabetologia, vol. 28, no. 7, pp. 412–419, 1985. View at Publisher · View at Google Scholar · View at Scopus
  27. A. A. Eissa Ahmed, N. M. Al-Rasheed, and N. M. Al-Rasheed, “Antidepressant-like effects of rosiglitazone, a PPARγ agonist, in the rat forced swim and mouse tail suspension tests,” Behavioural Pharmacology, vol. 20, no. 7, pp. 635–642, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Kashani, T. Omidvar, B. Farazmand et al., “Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression,” Psychoneuroendocrinology, vol. 38, no. 6, pp. 767–776, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. DE. Kemp, F. Ismail-Beigi, SJ. Ganocy, C. Conroy, K. Gao, and S. Obral, “Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity,” Journal of Affective Disorders, vol. 136, no. 3, pp. 1164–1173, 2012. View at Google Scholar
  30. N. L. Rasgon, H. A. Kenna, K. E. Williams, B. Powers, T. Wroolie, and A. F. Schatzberg, “Rosiglitazone add-on in treatment of depressed patients with insulin resistance: a pilot study,” The Scientific World Journal, vol. 10, pp. 321–328, 2010. View at Publisher · View at Google Scholar
  31. MS. Sadaghiani, M. Javadi-Paydar, MH. Gharedaghi, YY. Fard, and AR. Dehpour, “Antidepressant-like effect of pioglitazone in the forced swimming test in mice: the role of PPAR-gamma receptor and nitric oxide pathway,” Behavioural Brain Research, vol. 224, pp. 336–343, 2011. View at Google Scholar
  32. M. Salehi-Sadaghiani, M. Javadi-Paydar, M. H. Gharedaghi, A. Zandieh, P. Heydarpour, and Y. Yousefzadeh-Fard, “NMDA receptor involvement in antidepressant-like effect of pioglitazone in the forced swimming test in mice,” Psychopharmacology, vol. 223, no. 3, pp. 345–355, 2012. View at Google Scholar
  33. K. Sepanjnia, A. Modabbernia, M. Ashrafi, M. Modabbernia, and S. Akhondzadeh, “Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial,” Neuropsychopharmacology, vol. 37, no. 9, pp. 2093–2100, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Craft and G. S. Watson, “Insulin and neurodegenerative disease: shared and specific mechanisms,” The Lancet Neurology, vol. 3, no. 3, pp. 169–178, 2004. View at Publisher · View at Google Scholar
  35. M. Timonen, M. Laakso, J. Jokelainen, U. Rajala, V. B. Meyer-Rochow, and S. Keinanen-Kiukaanniemi, “Insulin resistance and depression: cross sectional study,” British Medical Journal, vol. 330, no. 7481, pp. 17–18, 2005. View at Google Scholar
  36. C. L. Raison, L. Capuron, and A. H. Miller, “Cytokines sing the blues: inflammation and the pathogenesis of depression,” Trends in Immunology, vol. 27, no. 1, pp. 24–31, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. D. E. Kemp, M. Schinagle, K. Gao et al., “PPAR-γ agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression,” CNS Drugs, vol. 28, no. 6, pp. 571–581, 2014. View at Publisher · View at Google Scholar
  38. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998. View at Google Scholar
  39. K. Fuenzalida, R. Quintanilla, P. Ramos et al., “Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis,” The Journal of Biological Chemistry, vol. 282, no. 51, pp. 37006–37015, 2007. View at Publisher · View at Google Scholar
  40. H. Kalonia, P. Kumar, and A. Kumar, “Pioglitazone ameliorates behavioral, biochemical and cellular alterations in quinolinic acid induced neurotoxicity: possible role of peroxisome proliferator activated receptor-γ (PPARγ) in Huntington's disease,” Pharmacology Biochemistry and Behavior, vol. 96, no. 2, pp. 115–124, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. N. C. Inestrosa, J. A. Godoy, R. A. Quintanilla, C. S. Koenig, and M. Bronfman, “Peroxisome proliferator-activated receptor γ is expressed in hippocampal neurons and its activation prevents β-amyloid neurodegeneration: role of Wnt signaling,” Experimental Cell Research, vol. 304, no. 1, pp. 91–104, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. S. S. Chung, M. Kim, J. S. Lee et al., “Mechanism for antioxidative effects of thiazolidinediones in pancreatic β-cells,” The American Journal of Physiology Endocrinology and Metabolism, vol. 301, no. 5, pp. E912–E921, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Sarandol, E. Sarandol, S. S. Eker, S. Erdinc, E. Vatansever, and S. Kirli, “Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative—antioxidative systems,” Human Psychopharmacology, vol. 22, no. 2, pp. 67–73, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Berk, D. L. Copolov, O. Dean et al., “N-acetyl cysteine for depressive symptoms in bipolar disorder-a double-blind randomized placebo-controlled trial,” Biological Psychiatry, vol. 64, no. 6, pp. 468–475, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Kumar, A. Vashist, and P. Kumar, “Potential role of pioglitazone, caffeic acid and their combination against fatigue syndrome-induced behavioural, biochemical and mitochondrial alterations in mice,” Inflammopharmacology, vol. 18, no. 5, pp. 241–251, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. K. K. Ryan, B. E. Grayson, K. R. Jones et al., “Physiological responses to acute psychological stress are reduced by the PPARγ agonist rosiglitazone,” Endocrinology, vol. 153, no. 3, pp. 1279–1287, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. B. García-Bueno, J. R. Caso, B. G. Pérez-Nievas, P. Lorenzo, and J. C. Leza, “Effects of peroxisome proliferator-activated receptor gamma agonists on brain glucose and glutamate transporters after stress in rats,” Neuropsychopharmacology, vol. 32, no. 6, pp. 1251–1260, 2007. View at Publisher · View at Google Scholar · View at Scopus